Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study
Journal of Clinical Oncology · 10.02.2024 · 42 (5) · 550-561
DOI: 10.1200/jco.23.00838 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.02.2024. Verfasst von Christiane Pott und 21 weiteren Autor:innen. Beteiligte Einrichtung: University Hospital Schleswig-Holstein, Kiel, Germany. Hauptthemen laut MEDLINE: Gallium, Lymphoma, Follicular. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 36 Literaturangaben.
Abstract (Originalsprache)
PURPOSE We report an analysis of minimal residual/detectable disease (MRD) as a predictor of outcome in previously untreated patients with follicular lymphoma (FL) from the randomized, multicenter GALLIUM (ClinicalTrials.gov identifier: NCT01332968 ) trial. PATIENTS AND METHODS Patients received induction with obinutuzumab (G) or rituximab (R) plus bendamustine, or cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or cyclophosphamide, vincristine, prednisone (CVP) chemotherapy, followed by maintenance with the same antibody in responders. MRD status was assessed at predefined time points (mid-induction [MI], end of induction [EOI], and at 4-6 monthly intervals during maintenance and follow-up). Patients with evaluable biomarker data at diagnosis were included in the survival analysis. RESULTS MRD positivity was associated with inferior progression-free survival (PFS) at MI (hazard ratio [HR], 3.03 [95% CI, 2.07 to 4.45]; P < .0001) and EOI (HR, 2.25 [95% CI, 1.53 to 3.32]; P < .0001). MRD response was higher after G- versus R-chemotherapy at MI (94.2% v 88.9%; P = .013) and at EOI (93.1% v 86.7%; P = .0077). Late responders (MI-positive/EOI-negative) had a significantly poorer PFS than early responders (MI-negative/EOI-negative; HR, 3.11 [95% CI, 1.75 to 5.52]; P = .00011). The smallest proportion of MRD positivity was observed in patients receiving bendamustine at MI (4.8% v 16.0% in those receiving CHOP; P < .0001). G appeared to compensate for less effective chemotherapy regimens, with similar MRD response rates observed across the G-chemo groups. During the maintenance period, more patients treated with R than with G were MRD-positive (R-CHOP, 20.7% v G-CHOP, 7.0%; R-CVP, 21.7% v G-CVP, 9.4%). Throughout maintenance, MRD positivity was associated with clinical relapse. CONCLUSION MRD status can determine outcome after induction and during maintenance, and MRD negativity is a prerequisite for long-term disease control in FL. The higher MRD responses after G- versus R-based treatment confirm more effective tumor cell clearance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University Hospital Schleswig-Holstein, Kiel, Germany.
- Department of Internal Medicine III, University Hospital of the Ludwig-Maximilians-University Munich, Munich, Germany.
- Institute for Medical Information Processing, Biometry, and Epidemiology, Faculty of Medicine, Ludwig-Maximilians-University Munich, Munich, Germany.
- Concord Repatriation General Hospital, University of Sydney, Sydney, NSW, Australia.
- HELIOS Klinikum, Erfurt, Germany.
- University of Ottawa, Ottawa Hospital, Ottawa, ON, Canada.
ORCID-Profile: Christiane Pott, Judith Trotman, Michael Herold, Richard van der Jagt, Jiri Mayer, Helen Brown, Eva Hoster
Zitieren
APA
Pott, C., Jurinovic, V., Trotman, J., Kehden, B., Unterhalt, M., Herold, M., Jagt, R. V., Janssens, A., Kneba, M., Mayer, J., Young, M., Schmidt, C., Knapp, A., Nielsen, T., Brown, H., Spielewoy, N., Harbron, C., Bottos, A., Mundt, K., …, & Hoster, E. (2024). Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study. Journal of Clinical Oncology, 42(5), 550-561. https://doi.org/10.1200/jco.23.00838
Vancouver
Pott C, Jurinovic V, Trotman J, Kehden B, Unterhalt M, Herold M, et al. Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study. Journal of Clinical Oncology. 2024;42(5):550-561. doi:10.1200/jco.23.00838
BibTeX
@article{Pott2024,
author = {Pott, Christiane and Jurinovic, Vindi and Trotman, Judith and Kehden, Britta and Unterhalt, Michael and Herold, Michael and Jagt, Richard van der and Janssens, Ann and Kneba, Michael and Mayer, Jiri and Young, Moya and Schmidt, Christian and Knapp, Andrea and Nielsen, Tina and Brown, Helen and Spielewoy, Nathalie and Harbron, Chris and Bottos, Alessia and Mundt, Kirsten and Marcus, Robert and Hiddemann, Wolfgang and Hoster, Eva},
title = {Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study},
journal = {Journal of Clinical Oncology},
year = {2024},
volume = {42},
number = {5},
pages = {550--561},
doi = {10.1200/jco.23.00838}
}
EUVIMED